JP6473938B2 - 抗線維化化合物、その方法および使用 - Google Patents

抗線維化化合物、その方法および使用 Download PDF

Info

Publication number
JP6473938B2
JP6473938B2 JP2016517101A JP2016517101A JP6473938B2 JP 6473938 B2 JP6473938 B2 JP 6473938B2 JP 2016517101 A JP2016517101 A JP 2016517101A JP 2016517101 A JP2016517101 A JP 2016517101A JP 6473938 B2 JP6473938 B2 JP 6473938B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
kynurenine
fibrosis
och
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016517101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521695A5 (cg-RX-API-DMAC7.html
JP2016521695A (ja
Inventor
ガハリー，アジズ
リ，ユンユアン
キラニ，ルハンギズ，ティー．
ハートウェル，ライアン
Original Assignee
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア filed Critical ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Publication of JP2016521695A publication Critical patent/JP2016521695A/ja
Publication of JP2016521695A5 publication Critical patent/JP2016521695A5/ja
Application granted granted Critical
Publication of JP6473938B2 publication Critical patent/JP6473938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016517101A 2013-06-05 2014-06-04 抗線維化化合物、その方法および使用 Active JP6473938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831404P 2013-06-05 2013-06-05
US61/831,404 2013-06-05
PCT/CA2014/000484 WO2014194407A1 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Publications (3)

Publication Number Publication Date
JP2016521695A JP2016521695A (ja) 2016-07-25
JP2016521695A5 JP2016521695A5 (cg-RX-API-DMAC7.html) 2017-07-20
JP6473938B2 true JP6473938B2 (ja) 2019-02-27

Family

ID=52007349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517101A Active JP6473938B2 (ja) 2013-06-05 2014-06-04 抗線維化化合物、その方法および使用

Country Status (14)

Country Link
US (1) US9737523B2 (cg-RX-API-DMAC7.html)
EP (1) EP3003298B1 (cg-RX-API-DMAC7.html)
JP (1) JP6473938B2 (cg-RX-API-DMAC7.html)
KR (1) KR102294405B1 (cg-RX-API-DMAC7.html)
AU (1) AU2014277568B2 (cg-RX-API-DMAC7.html)
CA (1) CA2914261C (cg-RX-API-DMAC7.html)
DK (1) DK3003298T3 (cg-RX-API-DMAC7.html)
ES (1) ES2978920T3 (cg-RX-API-DMAC7.html)
PH (1) PH12015502717B1 (cg-RX-API-DMAC7.html)
PL (1) PL3003298T3 (cg-RX-API-DMAC7.html)
RU (1) RU2726416C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201510003VA (cg-RX-API-DMAC7.html)
WO (1) WO2014194407A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201600015B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10779517B2 (en) 2017-01-31 2020-09-22 The Board Of Regents Of The University Of Oklahoma Animal wound model and methods of use
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
US20240226085A1 (en) * 2021-05-07 2024-07-11 Birchbiomed Inc. Kynrenine and derivatives thereof for treating atrophic scarring
CN119055650A (zh) * 2024-09-06 2024-12-03 上海市东方医院（同济大学附属东方医院） 犬尿喹啉酸在治疗慢性肝硬化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2005306585A1 (en) * 2004-11-17 2006-05-26 Nuon Therapeutics Pty Limited A method of modulating B cell functioning
HUP0700051A2 (en) * 2007-01-17 2008-09-29 Univ Szegedi Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation
SMT202100248T1 (it) * 2012-06-15 2021-05-07 Conaris Res Institute Ag Composizione farmaceutica contenente acido nicotinico e/o nicotinammide e/o triptofano per influenzare positivamente il microbiota intestinale

Also Published As

Publication number Publication date
CA2914261C (en) 2020-02-11
EP3003298A4 (en) 2017-03-22
NZ715579A (en) 2021-05-28
DK3003298T3 (da) 2024-06-17
KR102294405B1 (ko) 2021-08-25
RU2015156196A (ru) 2017-07-14
PL3003298T3 (pl) 2024-07-15
PH12015502717B1 (en) 2023-09-13
EP3003298B1 (en) 2024-03-20
EP3003298A1 (en) 2016-04-13
ZA201600015B (en) 2019-07-31
KR20160018676A (ko) 2016-02-17
BR112015030569A2 (pt) 2017-07-25
PH12015502717A1 (en) 2016-03-14
WO2014194407A1 (en) 2014-12-11
US9737523B2 (en) 2017-08-22
RU2015156196A3 (cg-RX-API-DMAC7.html) 2018-05-24
AU2014277568B2 (en) 2019-09-19
BR112015030569A8 (pt) 2020-01-07
ES2978920T3 (es) 2024-09-23
SG11201510003VA (en) 2016-01-28
AU2014277568A1 (en) 2016-01-28
US20160120857A1 (en) 2016-05-05
JP2016521695A (ja) 2016-07-25
CA2914261A1 (en) 2014-12-11
RU2726416C2 (ru) 2020-07-14

Similar Documents

Publication Publication Date Title
Luo et al. Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-β1/SMADs pathway
Raman et al. Integrin-linked kinase signaling promotes cyst growth and fibrosis in polycystic kidney disease
Tang et al. Piceatannol inhibits the IL-1β-induced inflammatory response in human osteoarthritic chondrocytes and ameliorates osteoarthritis in mice by activating Nrf2
JP6473938B2 (ja) 抗線維化化合物、その方法および使用
Ou et al. Targeting STING-mediated pro-inflammatory and pro-fibrotic effects of alveolar macrophages and fibroblasts blunts silicosis caused by silica particles
Gu et al. Akebia Saponin D suppresses inflammation in chondrocytes via the NRF2/HO-1/NF-κB axis and ameliorates osteoarthritis in mice
Wang et al. Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells
Lu et al. MicroRNA-21-regulated activation of the Akt pathway participates in the protective effects of H2S against liver Ischemia–reperfusion injury
Li et al. Renal Fibrosis Is Alleviated through Targeted Inhibition of IL-11–Induced Renal Tubular Epithelial-to-Mesenchymal Transition
Miao et al. Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating “PPAR-γ-glutaminolysis-DEPTOR” pathway in pulmonary fibrosis
He et al. Hydrogen sulfide regulates macrophage polarization and necroptosis to accelerate diabetic skin wound healing
Wu et al. 4-OI ameliorates bleomycin-induced pulmonary fibrosis by activating Nrf2 and suppressing macrophage-mediated epithelial-mesenchymal transition
Huang et al. Resatorvid (TAK-242) ameliorates ulcerative colitis by modulating macrophage polarization and T helper cell balance via TLR4/JAK2/STAT3 signaling pathway
Yasuda Activation of Akt leading to NF-κB up-regulation in chondrocytes stimulated with fibronectin fragment
US12006501B2 (en) Composition of drug targets and method of using thereof
Liu et al. MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through inhibition of TGF-β-induced CTGF expression in human lung fibroblasts: Involvement of MKP-1 activation
Pan et al. Holomycin, a novel NLRP3 inhibitor, attenuates cartilage degeneration and inflammation in osteoarthritis
Huang et al. A novel caffeic acid derivative prevents renal remodeling after ischemia/reperfusion injury
Cheng et al. DR7dA, a novel antioxidant peptide analog, demonstrates antifibrotic activity in pulmonary fibrosis in vivo and in vitro
CN117343122A (zh) 一种治疗炎症免疫性疾病的齐墩果酸酰胺衍生物、其制备方法及其用途
Yin et al. Peritoneal cavity-derived GATA6+ macrophages inhibit fibrosis through IL33 in endometrium
Kant et al. Mixed lineage kinase (MLK) controls tumor development and angiogenesis
NZ715579B2 (en) Anti-fibrogenic compounds, methods and uses thereof
BR112015030569B1 (pt) Uso de compostos anti-fibrogênicos
CN118416038B (zh) 2-(2-甲基丙氧基)苯胺在制备治疗炎症性疾病的药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190115

R150 Certificate of patent or registration of utility model

Ref document number: 6473938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250